Adial Pharma Appoints New CMO, Elects Director
Ticker: ADIL · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
Related Tickers: ADIL
TL;DR
Adial Pharma shakes up leadership with new CMO and board member, effective April 10, 2024.
AI Summary
Adial Pharmaceuticals, Inc. announced on April 10, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Ms. Karen L. Smith to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Smith's new role.
Why It Matters
These executive and board changes could signal a strategic shift or new direction for Adial Pharmaceuticals, potentially impacting its drug development and business strategy.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Adial Pharmaceuticals, Inc. (company) — Registrant
- Dr. Robert L. Smith (person) — Appointed Chief Medical Officer
- Ms. Karen L. Smith (person) — Elected to Board of Directors
- April 10, 2024 (date) — Effective date of appointments and elections
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer, Dr. Robert L. Smith?
The filing states Dr. Robert L. Smith was appointed Chief Medical Officer, but does not detail his specific responsibilities beyond this title.
What is the background or relevant experience of Ms. Karen L. Smith that led to her election to the Board of Directors?
The filing announces Ms. Karen L. Smith's election to the Board of Directors but does not provide details on her background or experience.
Are there any changes to the compensation structure for named executive officers as a result of these appointments?
The filing mentions compensatory arrangements of certain officers but does not specify if they have been altered due to the new appointments.
What is the expected impact of these leadership changes on Adial Pharmaceuticals' ongoing clinical trials or drug development pipeline?
The filing does not explicitly state the expected impact of these leadership changes on the company's clinical trials or drug development pipeline.
When were these changes officially effective according to the filing?
The earliest event reported in the filing is dated April 10, 2024, indicating the effective date for these changes.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2024-04-16 16:38:19
Filing Documents
- ea020390801-8k_adialpharm.htm (8-K) — 22KB
- 0001213900-24-033471.txt ( ) — 193KB
- adil-20240410.xsd (EX-101.SCH) — 3KB
- adil-20240410_lab.xml (EX-101.LAB) — 33KB
- adil-20240410_pre.xml (EX-101.PRE) — 22KB
- ea020390801-8k_adialpharm_htm.xml (XML) — 4KB
02 Departure of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 10, 2024, Adial Pharmaceuticals, Inc. (the "Company") provided Dr. Bankole A. Johnson with notice of the termination of the Company's consulting agreement with Dr. Johnson, entered into as of March 24, 2019, as amended as of March 22, 2022 and September 8, 2022 (the "Consulting Agreement"). The termination is effective May 17, 2024. As a result of the termination of the Consulting Agreement, effective as of May 17, 2024, Dr. Johnson will no longer serve as the Company's Chief Medical Officer.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 16, 2024 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer